Indivior PLC

Equities

INDV

GB00BN4HT335

Market Closed - London S.E. Other stock markets 11:35:11 2024-11-29 EST			5-day change	1st Jan Change
885.00 ^GBX	+1.43%		+3.81%	-25.32%

11-19	Indivior PLC Shares Results from a Randomized, Open-Label Sub-Study in Opioid-Dependent Participants Seeking Treatment	CI
11-15	Jerome Lande to Step Down from the Board of Indivior plc	CI

Presenter SpeechJason Thompson (Executives)We appreciate you...

This article is reserved for subscribers

Signed up already?

Not subscribed yet?

Latest news about Indivior PLC

Indivior PLC Shares Results from a Randomized, Open-Label Sub-Study in Opioid-Dependent Participants Seeking Treatment	11-19	CI
Jerome Lande to Step Down from the Board of Indivior plc	11-15	CI
Indivior to talk with Oaktree after accusations of "value destruction"	11-08	AN
Indivior Shareholder Oaktree Capital Calls for Board Refresh	11-08	MT
Oaktree Capital urges UK's Indivior to refresh board	11-07	RE
Oaktree Capital Sends a Letter to Indivior PLC	11-07	CI
Indivior completes refinancing of secured term loan	11-05	AN
Indivior Secures $400 Million Debt Financing	11-05	MT
Indivior PLC Completes Refinance of Secured Term Loan	11-05	CI
Indivior shares jump as backs guidance despite stiff competition	10-24	AN
Indivior PLC, Q3 2024 Earnings Call, Oct 24, 2024	10-24
Tranche Update on Indivior PLC's Equity Buyback Plan announced on July 25, 2024.	10-24	CI
Indivior PLC Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	10-24	CI
JPMorgan cuts Vistry; Goldman lowers Ceres	10-11	AN
Shares in Indivior plunge 19% as profit warning	10-10	AN
Stocks ease amid weak US jobs data and robust CPI	10-10	AN
Indivior's opioid treatment sales slump prompts second profit warning	10-10	RE
Indivior Shares Fall Pre-Bell After Lowering Fiscal Year 2024 Revenue Outlook	10-10	MT
Top Premarket Decliners	10-10	MT
Indivior PLC Provides Revenue Guidance for the Third Quarter of 2024	10-10	CI
Indivior PLC Revises Financial Guidance for the Fiscal Year 2024	10-10	CI
Indivior Gets FDA Priority Review on Prior Approval Supplement for Sublocade	10-07	MT
Indivior PLC's SUBLOCADE® Rapid Induction/Alternative Injection Site Prior Approval Supplement Receives FDA Priority Review	10-07	CI
Indivior Chair Graham Hetherington to retire at year-end	10-04	AN
Indivior PLC Announces Retirement of Graham Hetherington as Chair and from the Board	10-03	CI